| Popis: |
Background At present, there are insufficient prognostic markers for prostate cancer. The aim of this study was to evaluate abnormalities of β -catenin protein expression and subcellular localisation and to determine its relation to different clinicopathological features and disease-free survival in prostate cancer patients. Methods β -Catenin was determined by immunohistochemistry in 40 prostate cancer specimens, obtained from patients with different stages of prostate cancer (83% stage IV) who underwent a radical prostatectomy or TURP between 2006 and 2011. The membranous expression was semiquantitatively. Clinical records of these patients were studied for follow-up data. Findings β -Catenin was over-expressed Libyan patients with prostate cancer. There was no statistically significant difference in β -catenin immunoexpression as regards histopathological type, perineural invasion, tumour stage, biological recurrence. However, β -catenin over-expression showed significant correlation with old age ( p p Conclusions Changes in expression and cell distribution of β -catenin correlate with the progression of prostate adenocarcinoma, signifying a role of this molecule as a marker of progression and prognosis. Further investigations, on a larger and more heterogeneous population, should be carried out to validate and extend our results. |
Full Text from ScienceDirect